| Old Articles: <Older 4881-4890 Newer> |
|---|
 |
Chemistry World
May 30, 2008
Michael Gross |
Improving photodynamic cancer therapy Chemists in the UK and Canada have developed a new molecule that can help doctors to destroy cancer cells with unprecedented precision, using a technique known as photodynamic therapy (PDT).   |
The Motley Fool
May 30, 2008
Brian Orelli |
For Merck, Hindsight Hurts Even after dragging its feet for years, one has to wonder if Merck settled the Vioxx cases a little too quickly? |
The Motley Fool
May 30, 2008
Brian Orelli |
WuXi Woos Pharma Pharmaceutical outsourcing specialist WuXi PharmaTech proves that outsourcing to China isn't dead yet and neither are Chinese companies moving stateside. |
The Motley Fool
May 30, 2008
Brian Lawler |
PDL Shakeup Lifts Shares Shares of PDL BioPharma rise after a longtime board member, currently the company's interim CEO, departs. |
The Motley Fool
May 30, 2008
Brian Orelli |
No Love for Antibiotics From the FDA Wyeth gets an approvable letter for its antibiotic Tygacil. |
The Motley Fool
May 30, 2008
Brian Lawler |
Bristol-Myers' Cheap Pipeline Bet Bristol-Myers announces that it is acquiring development-stage drugmaker Kosan Biosciences for a net price of $190 million in cash. |
The Motley Fool
May 30, 2008
Brian Lawler |
Gilead Gets Synergistic Gilead Sciences newly acquired compound will play nicely with the drugmaker's existing products. |
FAO Today
May/Jun 2008 |
Department Case Studies: Reining in Receivables Crescent Healthcare uses outsourcing to increase cash flow on its year-old aging receivables by 50 percent, and in record time. |
The Motley Fool
May 29, 2008
Brian Lawler |
Ligand Loses, for Now The FDA sends Ligand Pharmaceutical this message: approval unlikely, try again later. |
The Motley Fool
May 29, 2008
Brian Lawler |
Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors. |
| <Older 4881-4890 Newer> Return to current articles. |
